Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

2005 • 44,461 citations

The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma

2002 • 3,769 citations

A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

1975 • 3,051 citations

A Leisurely Look at the Bootstrap, the Jackknife, and Cross-Validation

1983 • 2,903 citations

International Staging System for Multiple Myeloma

2005 • 2,696 citations

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

2003 • 2,642 citations

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

2005 • 2,457 citations

CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION

1998 • 1,551 citations

Selection bias in gene extraction on the basis of microarray gene-expression data

2002 • 1,432 citations

Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells

2004 • 1,395 citations

Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia

2004 • 1,353 citations

Multiple Myeloma

2004 • 1,219 citations

The molecular classification of multiple myeloma

2006 • 1,078 citations

Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells

2006 • 1,075 citations

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

2003 • 1,010 citations

NF-κB as a Therapeutic Target in Multiple Myeloma

2002 • 906 citations

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

1999 • 850 citations

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

2004 • 758 citations

Semi-Supervised Methods to Predict Patient Survival from Gene Expression Data

2004 • 722 citations

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

2003 • 721 citations

Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma

2005 • 687 citations

Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells

2002 • 655 citations

Clinical and biologic implications of recurrent genomic aberrations in myeloma

2003 • 648 citations

Advances in biology of multiple myeloma: clinical applications

2004 • 606 citations

Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

2003 • 597 citations

Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma

2005 • 554 citations

Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.

2001 • 544 citations

Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.

2001 • 481 citations

Reactive Oxygen Species Generation and Mitochondrial Dysfunction in the Apoptotic Response to Bortezomib, a Novel Proteasome Inhibitor, in Human H460 Non-small Cell Lung Cancer Cells

2003 • 458 citations

In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression

2003 • 388 citations

Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers

2005 • 374 citations

Overexpression of c-maf is a frequent oncogenic event in multiple myeloma that promotes proliferation and pathological interactions with bone marrow stroma

2004 • 365 citations

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

2005 • 356 citations

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

2002 • 353 citations

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

2000 • 333 citations

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

2002 • 324 citations

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]

1993 • 321 citations

Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective

2004 • 196 citations

A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains anIGH/MMSET fusion transcript

2003 • 194 citations

A molecular compendium of genes expressed in multiple myeloma

2002 • 186 citations

Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.

2002 • 185 citations

Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays

2002 • 172 citations

Prognostic factors and staging in multiple myeloma: a reappraisal.

1986 • 164 citations

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

1990 • 160 citations

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II

2002 • 159 citations

Prognostic value of pretreatment serum beta 2 microglobulin in myeloma: a Southwest Oncology Group Study [see comments]

1990 • 150 citations

A new staging system for multiple myeloma based on the number of S- phase plasma cells

1995 • 143 citations

Identification of genes modulated in multiple myeloma using genetically identical twin samples

2003 • 141 citations

Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression

2003 • 134 citations

Prognostic and Therapeutic Significance of Myeloma Genetics and Gene Expression Profiling

2005 • 131 citations

Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation

2003 • 125 citations

Molecular Classification of Multiple Myeloma: A Distinct Transcriptional Profile Characterizes Patients Expressing CCND1 and Negative for 14q32 Translocations

2005 • 122 citations

Gene Expression Profiling of Diffuse Large B-Cell Lymphoma

2003 • 106 citations

Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance

2005 • 98 citations

Tipifarnib and Bortezomib Are Synergistic and Overcome Cell Adhesion–Mediated Drug Resistance in Multiple Myeloma and Acute Myeloid Leukemia

2006 • 96 citations

Cell Adhesion Mediated Drug Resistance (CAM-DR): Role of Integrins and Resistance to Apoptosis in Human Myeloma Cell Lines

1999 • 90 citations

Why better prognostic factors for multiple myeloma are needed [editorial] [see comments]

1994 • 59 citations

Isolation and characterization of human multiple myeloma cell enriched populations

2000 • 46 citations

Bortezomib Continues Demonstrates Superior Efficacy Compared with High-Dose Dexamethasone in Relapsed Multiple Myeloma: Updated Results of the APEX Trail.

2005 • 41 citations

New treatments for multiple myeloma.

2005 • 28 citations

Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities

2000 • 22 citations

Current treatment options for myeloma

2005 • 14 citations

Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma [see comments]

1993 • 6 citations

Pharmacogenomics (PGx) Research in the APEX Randomized Multicenter International Phase 3 Trial Comparing Bortezomib and High-Dose Dexamethasone (Dex).

2005 • 1 citations